 CHICAGO--BUSINESS WIRE--MAIA Biotechnology, Inc. NYSE American: MAIA MAIA, the Company, a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical Oncology ESMO Congress 2022, being held from September 9th to 13th in Paris, France. THIO is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small ce 